Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID2)
|X-linked Severe Combined Immunodeficiency||Other: Gene transfer||Phase 1 Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Protocol No. 2 of Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Using a Self Retroviral Vector - SCID2|
- Assessment of immunological reconstitution at short term [ Time Frame: month 4 ]T cells proliferation T cells and B cells repertory by immunofluorescence T, NK and B Lymphocytes phenotyping Immunoglobulins dosage IgG, A, M, E and antibody production
- Molecular characterization of gene transfer [ Time Frame: every 15 days during 3 months, once per month until 6 months, every 3 months until year 1, every year until year 10 ]PCR of vector
- Analysis of activated proto-oncogene s expression [ Time Frame: every 4 months during 2 years and every 6 months indefinitely ]Immunofluorescence analysis of the relative expression of different families of TCR alpha beta et gamma delta LAM PCR analysis and sequencing of integration sites
|Study Start Date:||December 2010|
|Estimated Study Completion Date:||October 2016|
|Primary Completion Date:||July 2015 (Final data collection date for primary outcome measure)|
Other: Gene transfer
Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
The objective of this protocol is to reinitiate an ex vivo gene therapy clinical protocol to treat patients with SCID-X1 without HLA identical family donor nor HLA identical unrelated donor (bone marrow and cord blood) available in an adequate time with the clinical conditions of the patient at diagnosis (approximately 6 weeks). This clinical protocol No. 2 of SCID-X1 must be as efficient than the previous one but must involve a risk of insertional mutagenesis significantly reduced as compared to the first protocol.
The main purpose of the study is the study of toxicity: tolerance and incidence of serious adverse effects.
Secondary goals are the evaluation of immune reconstitution allowing the cure of infections present at the time of gene therapy, assessment of integration sites, and finally the long-term correction of immunosuppression.
- safety assessment : clinical effects, possible emergence of clonal lymphocyte proliferation, potential activation of proto-oncogene;
- efficacy assessment of ex vivo transduction of CD34 + hematopoietic stem cells of the patient through the use of retroviral vector pSRS11.EFS.IL2RG.pre;
- assessment of immune reconstitution : phenotype, number and function of different T, NK and B cells subpopulations;
- longitudinal evaluation of clinical effects in terms of improvement or complete restoration of immunity;
- biological efficacy assessment of this new vector SIN, assessment of molecular characteristics of retroviral integration.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01410019
|Paris, France, 75015|
|Study Director:||Alain Fischer, MD, PhD||Assistance Publique - Hôpitaux de Paris|